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http://www.biomedcentral.com/1471-2407/13/585RESEARCH ARTICLE Open AccessThe oncogenic properties of EWS/WT1 of
desmoplastic small round cell tumors are
unmasked by loss of p53 in murine embryonic
fibroblasts
Pratiti Bandopadhayay1, Anissa M Jabbour2,3, Christopher Riffkin2,3, Marika Salmanidis2,3, Lavinia Gordon4,
Dean Popovski4, Lin Rigby4, David M Ashley5, David N Watkins6, David M Thomas7, Elizabeth Algar6
and Paul G Ekert2,3,4*Abstract
Background: Desmoplastic small round cell tumor (DSRCT) is characterized by the presence of a fusion protein
EWS/WT1, arising from the t (11;22) (p13;q12) translocation. Here we examine the oncogenic properties of two
splice variants of EWS/WT1, EWS/WT1-KTS and EWS/WT1 + KTS.
Methods: We over-expressed both EWS/WT1 variants in murine embryonic fibroblasts (MEFs) of wild-type, p53+/−
and p53−/− backgrounds and measured effects on cell-proliferation, anchorage-independent growth, clonogenicity
after serum withdrawal, and sensitivity to cytotoxic drugs and gamma irradiation in comparison to control cells. We
examined gene expression profiles in cells expressing EWS/WT1. Finally we validated our key findings in a small
series of DSRCT.
Results: Neither isoform of EWS/WT1 was sufficient to transform wild-type MEFs however the oncogenic potential
of both was unmasked by p53 loss. Expression of EWS/WT1 in MEFs lacking at least one allele of p53 enhanced
cell-proliferation, clonogenic survival and anchorage-independent growth. EWS/WT1 expression in wild-type MEFs
conferred resistance to cell-cycle arrest after irradiation and daunorubicin induced apoptosis. We show DSRCT
commonly have nuclear localization of p53, and copy-number amplification of MDM2/MDMX. Expression of either
isoform of EWS/WT1 induced characteristic mRNA expression profiles. Gene-set enrichment analysis demonstrated
enrichment of WNT pathway signatures in MEFs expressing EWS/WT1 + KTS. Wnt-activation was validated in cell
lines with over-expression of EWS/WT1 and in DSRCT.
Conclusion: In conclusion, we show both isoforms of EWS/WT1 have oncogenic potential in MEFs with loss of p53.
In addition we provide the first link between EWS/WT1 and Wnt-pathway signaling. These data provide novel
insights into the function of the EWS/WT1 fusion protein which characterize DSRCT.* Correspondence: Ekert@wehi.edu.au
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Desmoplastic small round cell tumor (DSRCT) is a highly
aggressive tumor that most commonly affects adolescents
and young adults [1]. DSRCT has a dismal prognosis, and
novel therapeutic approaches are desperately needed. The
EWS/WT1 translocation t(11;22)(p13;q12) is pathogno-
monic for DSRCT [2], and most commonly fuses exon 7
of EWS to exon 8 of WT1 although break-points may vary
[3,4]. DSRCT are classified as soft tissue sarcomas and
have evidence of co-expression of epithelial markers (cyto-
keratin), mesenchymal markers (desmin and vimentin)
and neuronal markers (neuron-specific enolase), with the
cell of origin yet to be determined [1].
The EWS/WT1 protein comprises the N-terminal do-
main of EWS1 fused to zinc finger 2 of the WTI protein
[2]. WT1 contains a regulatory domain and four zinc fin-
gers required for DNA binding and RNA modulation
functions. Alternate splicing in exon 9 of WT1 and EWS/
WT1 generates an insertion of three amino acids lysine,
threonine and serine (KTS) between zinc fingers 3 and 4,
producing + KTS and –KTS isoforms [5]. While both
EWS/WT1-KTS and EWS/WT1 +KTS have been de-
scribed in DSRCT, it remains unclear whether the onco-
genic properties of EWS/WT1 derive from one or other
isoform and existing data is contradictory [5,6]. Although
EWS/WT1-KTS has been reported to transform NIH3T3
cells [5], EWS/WT1 +KTS has not been shown to have
oncogenic properties.
Most published data on the t(11;22)(p13;q12) transloca-
tion have focused on EWS/WT1-KTS. Reported transcrip-
tional targets regulated by EWS/WT1 include PDGFA [6],
IGFR1 [7], TALLA-1 [8] and BAIAP3 for EWS/WT1-KTS
[9] and LRRC15 for EWS/WT1 +KTS [10]. Only one gene,
ENT4, has been reported to be regulated by both [11].
These targets have been identified in immortalized or can-
cer cell lines such as NIH3T3 cells, and osteosarcoma cell
lines. The lack of patient derived DSRCT cell lines and
paucity of patient derived tumor samples reflect the rarity
of the tumor. Lack of in vivo models have hampered efforts
to identify potential therapeutic targets.
In this project we sought to examine the functional ef-
fects of over-expression of EWS/WT1-KTS and EWS/
WT1 +KTS in primary murine embryonic fibroblasts. We
show for the first time that oncogenic properties of both
isoforms are unmasked by loss of p53 function. Further
we provide the first links between the EWS/WT1 fusion
protein and canonical Wnt-pathway activation. These data
provide novel insights into the potential oncogenic roles
of EWS/WT1 in DSRCT.
Methods
Ethics approval was granted by the relevant human and/
or animal ethics research committees of the Royal
Children’s Hospital, Murdoch Childrens ResearchInstitute and Walter Eliza Hall Institute of Medical
Research, Victoria, Australia.Generating MEFs that express EWS/WT1 and confirming
expression of EWS/WT1
MEFs were generated from E14.5 embryos of C57BL6 mice,
and from p53-knockout mice [12]. p53 knock- out mice
were a kind gift from Dr Bouillet, Melbourne. Full-length
human EWS/WT1-KTS, EWS/WT1+KTS (gift from Dr.
Haber, Boston) or eGFP were cloned into the pF5xUAS-
SV40-puromycin lentiviral vector [13]. Cells were infected
with GEV16 lentivirus and pF5xUAS-SV40 containing
EWS/WT1 or eGFP. Expression of EWS/WT1 was con-
firmed following selection. Transcripts were also cloned
into a doxycycline-regulated Tet-Off lentiviral vector, pF 7×
tOp MCS RS PGK Hygro TetR VP16 (Gift from Dr. Silke,
Melbourne) [14]. Lentivirus was generated and cells in-
fected as previously described [14]. The dose of 4-OHT
was 0.1 μM and the dose of doxycycline was 500 ng/ml.
Whole cell lysates were generated using RIPA buffer with
phosphatase inhibitor and protease inhibitor cocktail at a
concentration of 1×104 cells/μL and boiled for 10 minutes
in protein sample buffer. Samples were electrophoresed on
10% or 12% SDS page gels (BioRad) and transferred to
nitrocellulose for antibody detection.
Proteins were detected by chemiluminescence using an
ECL kit (Amersham, UK). Antibodies used (1:1000 dilu-
tion) were anti-p21 (Santa Cruz Biotechnology, CA, USA:
Cat number SC-271532), anti p53 (Leica Biosystem’s
Novocastra, IL, USA Cat number: NCL-p53-CM5P), anti-
p27 (Cell Signaling Cat number :2552), anti-rabbit IgG
HRP (1:10000) (GE Healthcare Life Sciences, NY, USA
Cat number: Amersham NA934) and anti-mouse IgG
HRP (1:10000) (Sigma-aldrich, MO, USA Cat number:
HA2304). Anti-WT1 (Santa Cruz C-19) was used in a
1:500 dilution.Cell proliferation and immortalisation assays
Equal numbers of freshly generated MEFs expressing
eGFP, EWS/WT1-KTS or EWS/WT1 +KTS were plated
on 15 cm gelatinized plates DMEM/10% FCS and main-
tained in selection. Cells were split every three to four days
(1:4 to 1:5) and number of live cells counted.Anchorage independent clonogenic assays
1000 cells of p53+/+, p53+/− and p53−/− backgrounds ex-
pressing either eGFP (vector control), EWS/WT1-KTS or
EWS/WT1 +KTS were plated in DMEM, 20% FCS and
0.3% soft agar in six-well plates and incubated for 14 days.
Colonies greater than 2 mm were counted. Three inde-
pendent experiments were performed.
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10,000 cells of p53+/+, p53+/− and p53−/− backgrounds ex-
pressing either eGFP, EWS/WT1-KTS or EWS/WT1 +
KTS were plated on gelatinized 10 cm plates in DMEM
with either 1% or 2% FCS for 14 days and then fixed with
1% glutaraldehyde for 30 minutes and stained with crystal
violet. Colonies greater than 5 mm were counted. Three
independent experiments were performed.
Cell viability assays assessing response to
daunorubicin therapy
1000 cells per well of p53+/− and p53−/− background ex-
pressing either eGFP, EWS/WT1-KTS or EWS/WT1 +
KTS were plated in 96-well plates. Cells were treated with
varying doses of daunorubicin diluted in DMEM/10%FCS.
At 24 hours a formazoan dye based (WST-1) (Roche Ap-
plied Science, IN, USA Cat number:11644807001) cell-
viability assay reagent [15] was added (1:10) and incubated
for one hour at 37°C. Three independent experiments were
performed.Cell-cycle assay following treatment with radiation
Wild type MEFs expressing either eGFP, EWS/WT1-KTS
or EWS/WT1 +KTS were treated with 10 Gy gamma ir-
radiation. Cells were lysed in hypo-PI buffer (0.1% Na3Ci-
trate in ddH2O, 0.1% TritonX-100, 50 μg/ml Propidium
Iodide (Sigma), 25 μg/ml RNase A) and nuclear staining of
PI analysed by flow cytometry. Cell-cycle analysis was per-
formed on ModFit LT analytical software (Verity Software
House, ME, USA). Six independent pools of MEFs were
tested over two experiments.
Illumina microarray analysis
mRNA (DNase treated) from pools of four independent
embryos, expressing eGFP, EWS/WT1-KTS or EWS/
WT1 +KTS was extracted using the Qiagen RNeasy Mini
Kit (Qiagen Sciences, MD, USA Cat number:74104). Sam-
ples were labeled and hybridized to Illumina MouseWG-
6_V2 Expression BeadChips by the Australian Genome
Research Facility (AGRF, Melbourne, Australia).
The unnormalised sample probe and control probe pro-
files were exported from GenomeStudio (v1.6.0). Analysis
was carried out using the statistical programming lan-
guage R (version 2.13.0) using packages from the Biocon-
ductor project [16]. Data quality was confirmed using
Bioconductor packages arrayQualityMetrics and lumi
[17-19]. Normexp-by-control background correction,
quantile normalization and log2 transformation was per-
formed using the limma package [20]. Probes that failed to
achieve a GenomeStudio detection p-value of 0.05 on any
array were deemed to be not expressed, and removed from
subsequent analyses. Probes were re-annotated using the
ReMOATannotation tables [20].A linear model was fitted to test for differential expres-
sion between primary MEFs expressing eGFP, EWS/WT1-
KTS or EWS/WT1 +KTS. Array weights were calculated
to estimate relative quality weights for each array [21]. A
hypergeometric test was carried out to compute p-values
for over or under representation of gene ontologies [22].
For analyses of gene sets enriched among samples, gene
set enrichment analysis (GSEA) [23,24] was performed
with the C2 canonical pathway (CP) gene sets from
MSigDB [23] with the addition of two WT1 gene sets [25]
using standard parameters and gene-set permutations.
Our data have been deposited in NCBI’s Gene Expres-
sion Omnibus [26] are accessible through GEO Series ac-
cession number GSE42649 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE42649).
P53 sequencing and copy number analysis of MDM2
and MDM4
Genomic DNA from tumours were screened for p53 mu-
tations using high resolution melting analysis with or
without Sanger DNA sequencing as previously reported
[27,28]. Quantitative PCR was used to measure MDM2
andMDM4 copy-number as previously described [29].
Wnt qPCR assay
RNA was extracted from five DSRCT samples and also
from one patient derived human fibroblast cell line. qPCR
of WNT pathway members was performed using the RT2
Human WNT signaling pathway array (Qiagen). Data was
normalized to house-keeping genes and fold change calcu-
lated using the ΔΔCt method.
Immunohistochemistry
Paraffin sections of DSRCT were de-paraffinised using
xylene and ethanol. Antigen retrieval was performed
with 10nM sodium citrate pH 6. Antibodies used were
anti-β catenin (Millipore cat 06–734) and anti-p53:
(Dako cat p235189, clone 318-6-11) at a 1:100 dilution.
Detection was with Vectastatin Elite ABC Kit (Vector
Laboratories, CA, USA Cat number: pk-6101).
Results
EWS/WT1 (−KTS or + KTS) increases the rate of cell
proliferation of SV40 transformed MEFs
We used two lentiviral expression systems to over-express
EWS/WT1–KTS and EWS/WT1 +KTS in primary murine
fibroblasts (MEFs). These systems permitted EWS/WT1
expression to be induced by the addition of 4-Hydroxy
Tamoxifen (4-OHT) to cell cultures or for repression of
EWS/WT1 expression by the addition of doxycycline.
Expression of both + KTS and –KTS isoforms was con-
firmed in both lentiviral systems using Western blotting
(Figure 1A) and qPCR for mRNA expression (Figure 1B).
eGFP was included as a control.
Figure 1 EWS/WT1-KTS and EWS/WT1 + KTS expression co-operates with loss or inactivation of p53 to transform MEFs. (A) Western
blots of lysates from SV40 transformed MEFs expressing either eGFP, EWS/WT1-KTS or EWS/WT1 + KTS under the control of a 4-OHT inducible
promoter 48 hours after 4-OHT treatment (upper panel) or a doxycycline repressible promoter without doxycycline (lower panel). The anti-WT1
antibody detects a Cterminal-epitope in WT1. Arrow indicates EWS/WT1 to distinguish it from endogenous WT1. A non-specific band of similar
size to EWS/WT1 was observed in SV40-transformed, but not untransformed MEFs. (B) qPCR analysis of mRNA expression of eGFP, EWS/WT1-KTS
or EWS/WT1 + KTS in MEFs induced by either the 4-OHT inducible or tetracycline repressible expression systems. (C) Fold change in cell number
14 days after MEFs transformed by either SV40 or EIA/RAS were infected with eGFP, EWS/WT1-KTS or EWS/WT1 + KTS using the 4OHT inducible
system in SV40 transformed cells, and the doxycycline repressible system in EIA/RAS transformed cells. Cells were plated at equal densities and
counted and re-plated at the same dilution every 3–4 days. Data represent the mean ± SEM of three independently generated pools of MEFs
tested in three independent experiments. (D) MEFs derived from littermate wildtype (upper panel), p53+/− (middle panel) and p53−/−(lower
panel) mice were infected with doxycycline repressible eGFP, EWS/WT1-KTS or EWS/WT1 + KTS and then plated at equal density. Cells were
counted and re-plated on the indicated days. Values are mean ± SEM of three independently generated and infected pools of MEFs tested over
three independent experiments. # denotes a p value of 0.003 and * denotes a p value of 0.004 with Student’s t-test comparing eGFP to EWS/
WT1–KTS and eGFP to EWS/WT1 + KTS. Representative images of morphology of MEFs at 22 days are shown.
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pression, we examined the effect of EWS/WT1 expression
on proliferation of MEFs transformed either with SV40
large T antigen or E1A/RAS. Rate of cell proliferation was
measured by cell counts over a 14-day time course and
fold-change determined (Figure 1C). Expression of either
EWS/WT1 isoform increased proliferation rates compared
to eGFP controls in multiple, independent pools of SV40
large T antigen transformed MEFs (p value <0.05) but not
E1A/RAS transformed MEFs. The magnitude of the in-
crease was modest because these cells are already trans-
formed, but robustly repeatable. In all cell lines tested and
in all independent experiments, EWS/WT1 functioned to
promote proliferation in SV40 large T antigen transformed
but not E1A/RAS transformed MEFs. These data indicate
that both isoforms of EWS/WT1 increase cell proliferation
specifically in cells transformed with SV40 large T antigen.
This suggests EWS/WT1 may co-operate with the loss of
specific tumor suppressor pathways.
EWS/WT1 oncogenic functions are evident in cells lacking
one or both alleles of p53
The increased cell proliferation observed in MEFs trans-
formed by SV40 expressing EWS/WT1 led us to
hypothesize that EWS/WT1 co-operates with loss of p53
to promote proliferation. To investigate this, we infected
freshly isolated MEFs from E14.5 embryos derived from
crosses of p53+/− mice, with lentivirus encoding either
EWS/WT1 isoform or eGFP. For these, and subsequent
experiments the doxycycline repressible lentiviral expres-
sion system was used, due to increased infection efficiency
compared to the 4-OHT-inducible system.
Cells were continuously cultured, counted and re-
plated every third day over a three-week time course
(Figure 1D). In wild-type MEFs, neither EWS/WT1 iso-
form was sufficient to permit unrestricted division or
the development of foci (Figure 1D upper panel), and
wild type cells were unable to be maintained in culture
beyond three weeks. In contrast, in p53+/− MEFs both
EWS/WT1 + KTS and EWS/WT1–KTS induced the de-
velopment of foci and significantly increased the rate of
proliferation compared to eGFP controls (Figure 1D
middle panel). eGFP expressing p53+/− cells eventually
stopped proliferating while those expressing EWS/WT1
did not. In p53−/− cells, whilst foci formed independ-
ently of infection with EWS/WT1, they were more fre-
quent and the proliferation rate was increased in cells
expressing either EWS/WT1 isoform (Figure 1D lower
panel). p53+/− cells expressing EWS/WT1-KTS or
EWS/WT1 + KTS could be maintained in culture indef-
initely while those expressing eGFP could not. These
data confirm the ability of EWS/WT1 to induce foci for-
mation and increase proliferation rates of MEFs is re-
vealed by the loss of at least one copy of p53.We next determined whether EWS/WT1 could promote
colony formation after serum deprivation. Equal numbers
of wild-type, p53+/− and p53−/− MEFs expressing EWS/
WT1 +KTS, EWS/WT1-KTS or eGFP were cultured in
media containing 1% or 2% fetal calf serum (Figure 2). Ex-
pression of EWS/WT1-KTS and EWS/WT1 +KTS was
confirmed by western immunoblotting (Figure 2A). After
14 days, cells were fixed and stained with crystal violet
(Figure 2B) and number of colonies greater than 5 mm
diameter counted (Figure 2C). In 1% serum, EWS/
WT1 over-expression significantly increased colony
numbers in p53−/− MEFs compared to eGFP controls,
but no effect was observed in p53+/− or wild-type
MEFs. In 2% serum, EWS/WT1 expressing cells also
rescued p53+/− MEFs, which were able to form col-
onies. Under these less stringent conditions, EWS/
WT1 + KTS and EWS/WT1–KTS maintained the via-
bility of a proportion of p53+/− cells and permitted
proliferation. These data indicate that both EWS/WT1
isoforms can protect cells from serum deprivation and
enhance colony formation in limiting serum concen-
trations in MEFs lacking one or both copies of p53.
We assayed anchorage independent growth in MEFs
over-expressing EWS/WT1 by culturing wild-type, p53+/−
or p53−/− MEFs expressing EWS/WT1-KTS, EWS/
WT1 + KTS or eGFP in soft agar and counted the num-
ber of colonies greater than 2 mm diameter present
after two weeks (Figure 3A). As expected, the rate of an-
chorage independent growth in wild-type MEFs over-
expressing eGFP, was very low (0.2% of all cells plated).
The deletion of both copies of p53 resulted in a subtle,
EWS/WT1-independent increase in numbers of col-
onies. Over-expression of EWS/WT1-KTS or EWS/
WT1 + KTS, in p53+/− and p53−/− MEFs, significantly
increased the number of colonies compared to cells ex-
pressing eGFP. These data show that EWS/WT1 co-
operates with p53-deletion to also promote anchorage
independent growth.
Cells expressing EWS/WT1 are resistant to daunorubicin-
induced cell death and radiation induced cell cycle arrest
We hypothesized that expression of EWS/WT1 may
also confer resistance to p53-dependent stimuli, such as
apoptosis in response to chemotherapeutic drugs or cell
cycle arrest following gamma-irradiation. We used
daunorubicin in these experiments, as an example of a
well-known cytotoxic chemotherapeutic agent.
Wild-type MEFs expressing eGFP, EWS/WT1-KTS
or EWS/WT1 + KTS were treated with daunorubicin
and cell viability determined using a tetrazolium salt
(WST-1) cell viability assay (Figure 3B). In this assay, an
absorbance value of 1 indicates equal numbers of viable
cells in treated and control samples. Values less than 1
result from cell loss in treated cells and values greater
Figure 2 EWS/WT1-KTS and EWS/WT1 + KTS enhances clonogenicity in p53+/− or p53−/− MEFs in reduced serum. (A) Western blot
analysis of lysates derived from wild-type, p53+/−, and p53−/− background MEFs which were infected with doxycyline repressible eGFP, EWS/
WT1-KTS or EWS/WT1 + KTS lentiviral particles, showing expression of EWS/WT1 in the absence of doxycycline. (B) Representative images from
one experiment showing MEF colonies of the indicated genotype expressing eGFP, EWS/WT1-KTS or EWS/WT1 + KTS, plated at 1× 105 cells per
plate and cultured in 1% or 2% fetal calf serum. After 14 days cells were fixed with glutaraldehyde and stained with crystal violet. (C) Mean
number of colonies (from three independent experiments) greater than 5 mm of cells cultured in 1% (left panel) or 2% (right panel) serum on day 14.
Error bars show± SEM from three independent experiments. # denotes a p value of <0.05 as determined by Student’s t-test comparing eGFP to
EWS/WT1-KTS and eGFP to EWS/WT1 + KTS.
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treated cells. In wild-type MEFs, daunorubicin reduced
cell viability in a dose dependent manner (Figure 3B).
EWS/WT1 expression significantly reduced the drop in
absorbance at each dose compared to eGFP controls,
conferring partial protection to daunorubicin. The p53
dependent nature of treatment with daunorubicin was
confirmed by treating p53−/− cells, where minimal tox-
icity was observed following treatment with the same
doses of daunorubicin (Additional file 1: Figure S1).
Wild type MEFs were irradiated with 10Gy and cell
cycle analysis performed (Figure 3C). Four-hoursfollowing irradiation, most eGFP expressing cells had
exited the cell cycle and were temporarily arrested in
G1. These cells began dividing again by 24 hours
post irradiation. In contrast, over-expression of EWS/
WT1 + KTS or EWS/WT1–KTS delayed G1 cell cycle
arrest to 12-hours and reduced the proportion of cells
undergoing G1 arrest. We observed a higher proportion
of cells in S-phase in those lines expressing EWS/WT1-
KTS or EWS/WT1 + KTS compared to eGFP controls
four hours following radiation. EWS/WT1 expressing
cells resumed proliferation more rapidly, with an in-
crease in the number of cells in S phase at 24 hours
Figure 3 EWS/WT1-KTS and EWS/WT1 + KTS increase anchorage independent growth and confer resistance to daunorubin induced
apoptosis and cell cycle arrest following radiation. (A) 1x104 p53 wild-type, p53+/− or p53−/− MEFs expressing eGFP, EWS/WT1-KTS or EWS/
WT1 + KTS were plated in soft agar and the number of colonies greater than 2 mm counted after 14 days. Values are mean ± SEM of three
independently generated and infected pools of MEFs for each genotype tested in three independent experiments. P values of less than 0.05 as
determined by Student’s t-tests are shown. (B) Viability assay of cells treated with daunorubicin (0.5 μg/ml) for 24 hours. The data show the
ratio of WST1 absorbance of treated cells to the same number of untreated cells. Values are mean ± SEM of three independent experiments.
P values < 0.05 as determined by Student’s t-tests are shown. (C) Wild-type MEFS were irradiated with 10Gy gamma radiation and cell cycle
analysis performed at the indicated time points by staining cells with hypotonic propidium iodide solution. Cell-cycle analysis was performed
using FACS analysis and the Modfit software package. % of cells in G0/G1, S phase and G2 at baseline, 4, 12 and 24 hours post radiation are
shown. Values represent mean of three independent experiments. ** represent p values <0.05 in the comparison of % of cells in S phase and
G1 compared to eGFP controls, as determined by Student’s t-tests.
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the hypothesis that EWS/WT1 over-expression attenu-
ates radiation-induced cycle arrest compared to eGFP
controls.
EWS/WT1 does not block p53 up-regulation in response
to daunorubicin
To determine if EWS/WT1 over-expression influenced
p53 expression, we probed lysates from wild-type MEFs
expressing eGFP, EWS/WT1 + KTS or EWS/WT1–
KTS treated with daunorubicin with antibodies to de-
tect p53, p21 and p27 (Additional file 2: Figure S2).p53 expression levels in untreated cells (time 0) was
similar in all cells. No difference in p53 up-regulation
was observed in cells expressing EWS/WT1 after
daunorubicin treatment compared to eGFP controls.
These data indicate that while EWS/WT1 expression
appeared to attenuate p53 function, it did not directly
block p53 expression.
MDM2 and MDM4 copy number amplification in DSRCT
Our data suggest that the oncogenic functions of EWS/
WT1 are evident when tumor suppressor function of p53
is lost. We screened 15 samples of DSRCT (Additional file
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series of tumors, no loss-of-function mutations or dele-
tions in p53 were detected (data not shown). Sections
from six of these tumors were available for immunohisto-
chemistry for p53 analysis; three of them were found to
have nuclear accumulation of p53 in greater than 20% of
tumor cells (Figure 4A and 4B).
Copy-number amplifications of MDM2 and MDM4
have been frequently observed in sarcomas and are an im-
portant mechanism of p53 inactivation [29]. We used a
quantitative PCR assay to measure MDM2 and MDM4
copy-number levels. We found copy-number gains andFigure 4 DSRCT have evidence of nuclear immuno-reactivity of p53 a
DSRCT. (A) % of cells with p53 nuclear immuno-reactivity in five samples o
localization of p53 was scored in at least five (5–10) independent fields (20
image of DSRCT sample with anti-p53 immuno-staining. Arrows depict exa
number analysis as determined by qPCR in 15 primary DSRCT tumors (#1-1
for each sample relative to a normal female blood DNA control (normal co
Real-time quantitative PCR was performed using primers for MDM2, MDM4
control for each sample).amplification of MDM2 and/or MDM4 in at least ten out
of fifteen tumors examined (Figure 4C). Ten tumors (66%)
had copy number gain of MDM2 (>5 fold increase) and
eight (53%) had a greater than five fold increase in copy
number of MDM4. Five tumors (33%) had high-level copy
number amplification ofMDM2 with greater than ten fold
increase and six (40%) had amplification of MDM4 with
greater than ten fold increase. Three of the 15 tumors
(20%) had high-level co-amplification of both MDM2 and
MDM4 (greater than ten fold increase in copy number).
These data confirm the presence of copy-number gains or
amplifications ofMDM2 and/orMDM4 in DSRCT.nd evidence of MDM2/MDM4 copy-number amplification in
f DSRCT stained with anti-p53. The number of cells with nuclear
× magnification). Values represent mean ± SEM. (B) Representative
mples of cells with nuclear p53 staining. (C) MDM2/MDM4 copy
5). Data represent the copy number (average and standard deviation)
ntrol) and the T778 liposarcoma cell line that has MDM2 amplification.
, or a non-amplified region of Chr17 (as an internal normalisation
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KTS identifies canonical Wnt-pathway activation
We performed expression profiling to determine how each
EWS/WT1 isoform altered gene-expression in MEFs com-
pared to eGFP controls. Four independently generated
pools of wild-type MEFs were infected with doxycyline re-
pressible EWS/WT1 + KTS, EWS/WT1-KTS or eGFP, se-
lected with hygromycin and total RNA harvested and
analysed using Illumina MouseWG-6_V2 Expression
BeadChips (see Methods). Hierarchical clustering showed
that the individual infections within each pool of MEFs,
that is, eGFP and EWS/WT1 +KTS or EWS/WT1–KTS
were closely related to one another, and that samples clus-
tered according to the embryo from which the MEFs were
generated (Additional file 4: Figure S3). Multidimensional
scaling and proportion of variance analysis after correction
for embryo from which cells were generated indicated that
samples next clustered according to the transgene over-
expressed (Additional file 4: Figure S3B).
Analysis of differentially expressed genes confirmed that
expression of EWS/WT1-KTS or EWS/WT1 +KTS re-
sults in distinct gene expression profiles compared to each
other, and also compared to eGFP controls (Figure 5A and
Additional file 5: Table S2). Eleven genes were differen-
tially expressed between cells expressing eGFP compared
to cells expressing either EWS/WT1 isoform, 59 genes
were differentially expressed between eGFP cells and
EWS/WT1-KTS cells and 132 genes were differentially
expressed between eGFP cells and EWS/WT1 +KTS cells
(p value < 0.05, q value < 0.1; Additional file 3: Table S1).
None of the previously reported targets of EWS/WT1-
KTS (PDGFA1, IGFR1, TALLA-1, BAIAP3, ENT4) or
EWS/WT1 +KTS (LRRC15 or ENT4) were observed to
be differentially expressed in this analysis, using our de-
fined threshold of q value < 0.1.
We performed an unbiased screen of pathways altered
by expression of EWS/WT1-KTS or EWS/WT1 +KTS
(using the Gene Set Enrichment Algorithm and the C2
(CP) set of signatures with addition of WT1 gene sets
[25]) compared to eGFP controls. We found significant al-
teration of 58 pathways (p value < 0.05, q value <0.25;
Additional file 6: Table S3) between cells expressing eGFP
and either isoform of EWS/WT1. We observed alteration
of 171 pathways in cells expressing EWS/WT1-KTS com-
pared to eGFP controls and 17 pathways in cells express-
ing EWS/WT1 +KTS (Additional file 6: Table S3).
The KIM_WT1_TARGETS_UP gene set was the 9th
most enriched pathway in cells expressing EWS/WT1-KTS
compared to eGFP controls (q value <0.01, Additional
file 6: Table S3 and Figure 5B) however this pathway
was not found to be significantly enriched in cells ex-
pressing EWS/WT1 + KTS compared to eGFP controls.
This is not surprising as the KIM_WT1_TARGETS_UP
genes set was defined largely by genes up-regulated byover-expression of the WT1-KTS isoform [25]. This
finding, however, confirms overlap between EWS/WT1
and WT1 target genes.
Four of the 17 pathways enriched in cells expressing
EWS/WT1 +KTS involved genes from Wnt and Sonic
Hedgehog activation pathways (Figure 5C). There is sig-
nificant overlap of genes in the Wnt and Sonic Hedgehog
genesets, and indeed interactions between the functions of
these gene sets [30]. Wnt7b was observed to be in the top
40 genes up-regulated in cells expressing EWS/WT1 +
KTS compared to eGFP.
We therefore hypothesized that expression of EWS/
WT1 + KTS would result in up-regulation of canonical
Wnt-pathway signaling. We used 293 T cells, which
have minimal endogenous Wnt pathway activation, to
overexpress eGFP, EWS/WT1-KTS or EWS/WT1 +
KTS using our doxycyline-repressible lentiviral expres-
sion system to examine cellular localization of β-catenin
using fluorescence microscopy (Figure 5D). Nuclear β-
catenin localization is a marker of activation of canon-
ical Wnt-pathway signaling. We found that in eGFP
control cells over-expressing cells, β-catenin was pre-
dominantly localized to the cell membrane, with min-
imal nuclear localization. In the presence of EWS/
WT1-KTS expression, there was increased expression
of total β-catenin compared to eGFP controls, however
this did not appear to be localized to the nucleus. When
EWS/WT1 +KTS was expressed, total expression of β-
catenin was also increased compared to eGFP controls,
however there was also evidence of increased β-catenin
localization in the nucleus, consistent with Wnt-pathway
activation. This was diminished when cells were treated
with doxycycline. This data suggests that enforced EWS/
WT1 +KTS expression results in β-catenin nuclear
localization and Wnt-pathway activation. EWS/WT1-KTS
also appeared to increase total β-catenin expression com-
pared to eGFP controls, however this was not specific to
nuclear localization. The mechanism for the observed
over-expression for total β-catenin is yet to be determined.
We then examined a cohort of five DSRCT tumor sam-
ples for which there was sufficient material for evidence of
Wnt-activation by quantitative PCR analysis and β-catenin
immunhistochemistry. Each of these five tumors expressed
both the EWS/WT1-KTS and EWS/WT1 + KTS fusion
protein. We found evidence of differential expression of
mRNA of 59 Wnt-pathway genes (9 down-regulated)
in the five tumors compared to fibroblast controls
(Figure 6A and Additional file 7: Table S4). Further,
there was evidence of Wnt-activation in these same tu-
mors as determined by nuclear β-catenin immunoreac-
tivity localization (Figure 6B and Additional file 8:
Figure S4). Interestingly one of the tumors (Additional
file 8: Figure S4C-E) had two distinct populations of
cells, one with spindle shaped morphology and the
Figure 5 MEFs expressing EWS/WT1-KTS or EWS/WT1 + KTS have distinct expression profiles and EWS/WT1 + KTS expression is
associated with up-regulation of canonical Wnt pathway signaling. (A) Heat map of differentially expressed probes identified in primary
MEFs expressing EWS/WT1 + KTS, eGFP controls and EWS/WT1-KTS. The comparison is of four independently generated pools of MEFs each
infected with EWS/WT1 + KTS, EWS/WT1-KTS or GFP. (B) GSEA plot depicting enrichment of the KIM_WT1_TARGETS_UP gene set in lines expressing
EWS/WT1-KTS compared to eGFP controls. (C) Wnt related gene sets enriched in EWS/WT1 + KTS expressing cells (left) and GSEA plot of
PID_WNT_Signaling_Pathway geneset (right). (D) Immunocytochemistry of 293 T cells infected with doxycycline repressible eGFP, EWS/WT1-KTS or
EWS/WT1 + KTS. Cells are shown in the absence of doxycyline (panel on top and also with the presence of doxycycline treatment (thus doxycycline
repressed) for 48 hours (panel on bottom). Cells are stained with DAPI for nuclear staining (blue) and β-catenin antibody with secondary anti-goat Alexa
Fluor (red). β-catenin translocation from the cellular membrane to the nucleus is a marker of canonical Wnt-pathway activation.
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Nuclear β-catenin immunoreactivity was restricted to
the small round cells, consistent with canonical Wnt-
activation in these cells. Taken together these data
support the hypothesis that EWS/WT1 results in up-
regulation of canonical Wnt-pathway signaling. This is
further supported by evidence of Wnt-pathway activa-
tion in five DSRCT samples examined.Discussion
We have shown for the first time that both isoforms of
EWS/WT1 can behave as oncogenes when over-expressed
by promoting cell proliferation, anchorage-independent
growth, clonogenicity and resistance to apoptotic stimuli
in MEFs with loss of p53 function. Analysis of DSRCT
demonstrated nuclear-immunoreactivity of p53 and amp-
lification of MDM2 and MDM4 in the human tumors,
Figure 6 Canonical Wnt pathway activation in DSRCT. (A) Scatterplot of fold differences in expression of Wnt-pathway genes in five DSRCT
tumors compared to fibroblast control. Lines represent no change in gene expression in DSRCT samples compared to fibroblast controls and these
genes are represented by the black symbols. Genes to the left of these lines (red symbols) represent Wnt-pathway genes that are up-regulated in
DSRCT samples compared to fibroblast controls while those to the right (green symbols) represent genes that are down-regulated in DSRCT compared
to fibroblast controls. (B) Representative images of three samples (Tumors 1–3) of DSRCT stained with antibody for β-catenin. Negative antibody
controls are shown. Red arrows indicate examples of cells with nuclear reactivity, consistent with canonical Wnt-pathway activation.
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function. In addition, we present what is, to our knowledge,
the first evidence of an association between EWS/WT1 +
KTS expression and canonical Wnt-pathway signaling.
Neither EWS/WT1-KTS or EWS/WT1 +KTS was suffi-
cient to promote proliferation and survival in wild type
MEFs. The oncogenic properties of both, however, were
unmasked by loss of p53 function. We thus show the first
link between EWS/WT1 function and loss of p53 function.
There are several well-described mechanisms by which p53
function is repressed in pediatric tumors including retino-
blastoma [31] or sarcoma [32]. These include p53 mutation
or copy-number variation of MDM2 and MDM4/MDMX
[29].MDM2 amplification is one of the most frequently ob-
served recurrent gene amplifications in The Cancer Gen-
ome Atlas pan-cancer analyses of copy-number variations,
and in particular sarcomas [33]. Copy-number amplifica-
tion of MDM2 and MDM4 has also been specifically re-
ported in Ewing’s Sarcoma [29], and co-amplification of
both have been observed in a sub-set of sarcomas [34].
The clinical relevance of the finding is reinforced by the
studies of the human DSRCT samples. These are necessar-
ily limited in number because of the rarity of the tumor,
but nevertheless, a substantial number had MDM2 and/orMDM4 copy-number amplification. A limited screen of
p53 mutations did not identify well characterized loss-of-
function mutants, however a larger and more comprehen-
sive profiling with for example whole exome sequencing
would be required to be certain of the true rate of p53
mutations in this tumor sub-type. Thus we cannot exclude
the possibility that mutations in other tumor suppressor
pathways could also co-operate to drive EWS/WT1 onco-
genic function.
DSRCT is a difficult to treat tumor with a dismal prog-
nosis. Loss of p53 function may contribute to this aggres-
sive phenotype. Our data suggested that EWS/WT1
expression contributes to resistance to chemotherapeutic
drugs like daunorubicin or gamma irradiation. More suc-
cessful treatments will require a deeper understanding of
the biology of the tumor and further characterization of
genomic profiles of these tumors, with for example whole-
genome sequencing, may be fruitful.
It is intriguing that we have identified Wnt-pathway acti-
vation in our MEF models of EWS/WT1 expression and
corroborative evidence for a small number of human sam-
ples. The Wnt-pathway is implicated in many human malig-
nancies such as medulloblastoma [35], rhabdomyosarcoma
[36], colon cancer [37] and breast cancer [38], through both
Bandopadhayay et al. BMC Cancer 2013, 13:585 Page 12 of 14
http://www.biomedcentral.com/1471-2407/13/585activation of canonical and non-canonical signaling. This
observation can now be pursued in future work to investi-
gate whether the oncogenic properties that we observed in
cells expressing EWS/WT1 are dependent on Wnt-
activation, and elucidate the mechanism by which EWS/
WT1 over-expression activates Wnt-signaling.
Our expression analysis of differentially expressed genes
following induction of either EWS/WT1-KTS or EWS/
WT1 +KTS did not confirm previously reported targets of
the fusion protein. This may reflect differences between
our expression system and cell models and those of others.
However, an important feature of our project is the inclu-
sion of four independent biological replicates of primary
cell lines in an unbiased screen for all differentially
expressed mRNAs following over-expression of EWS/
WT1. This allowed a pure examination of the effects of
EWS/WT1 expression on genome-wide gene expression.
An interesting observation in our analysis was of signifi-
cant enrichment of expression of WT1-KTS associated
genes in cells expressing EWS/WT1-KTS, suggesting an
overlap in potential target genes of WT1 and EWS/WT1.
Further studies focusing on direct transcriptional targets
(ChIP-seq) and proteomic analyses will further our under-
standing of the function of EWS/WT1.
Using the tetracycline repressible lentiviral expression
vector we consistently observed higher levels of expression
of EWS/WT1 + KTS compared to EWS/WT1-KTS. We
therefore cannot conclude whether one splice variant has
greater potency in inducing the functional changes ob-
served compared to the other. Nevertheless, in our model
system, expression of both EWS/WT1-KTS and EWS/
WT1 +KTS was above the threshold required to induce
functional effects. It has been shown that the insertion of
the KTS amino acids changes the conformation of the
DNA binding sites in WT1, and it is likely that the differ-
ences in expression profiles observed between cells
expressing either EWS/WT1-KTS or EWS/WT1 +KTS is
secondary to this.
While we have observed functional changes with over-
expression of both isoforms of EWS/WT1 in MEFs, much
work remains to be completed in order to understand how
these splice variants contribute to tumor formation. It is
likely that their oncogenic potential is highly context
dependent. In our model system we have examined effect
on over-expression in MEFs – in future work it will be im-
portant to examine this in other contexts that are more
relevant to the human disease, such as over-expression in
human mesenchymal stem cells. Finally, the ability of the
EWS/WT1 fusion protein to generate tumors in vivo
remains to be determined in these different contexts.
Conclusion
In conclusion, we have expanded the knowledge of the
function of the EWS/WT1 transgene in DSRCT byshowing that both isoforms of the EWS/WT1 can func-
tion as an oncogene. We have established novel links be-
tween the oncogenic functions of EWS/WT1 and loss of
tumor suppressor genes such as p53, and between EWS/
WT1 expression and Wnt-pathway activation. These novel
insights into the function of EWS/WT1 may provide a
way forward for further research of this fusion protein and
its role in a rare but lethal malignancy.
Additional files
Additional file 1: Figure S1. Daunorubicin induced toxicity is p53
dependent in MEFs. Ratio of cell viability of cells treated with
daunorubicin (0.5μg/ml) for 24 hours to untreated MEFs of p53−/− MEFs
expressing GFP, EWS/WT1-KTS or EWS/WT1 + KTS as measured by
colorimetric cell viability assay. Values represent mean ± SEM of three
independent experiments performed in independently generated pools
of MEFs.
Additional file 2: Figure S2. EWS/WT1 does not affect p53
up-regulation following treatment with daunorubicin. Representative
western blots of p53, MDM2, p21 and p27 following daunorubicin
treatment of wild type MEFs expressing eGFP, EWS/WT1-KTS or EWS/WT1
+ KTS. Lysates were generated at time points indicated.
Additional file 3: Table S1. Desmoplastic Small Round Cell Tumors
used in validation studies.
Additional file 4: Figure S3. Hierarchical clustering and
multidimensional scaling analysis of gene expression data. (A) Hierarchical
clustering of four independent pools of MEFs expressing GFP, EWS/WT1-KTS
or EWS/WT1 + KTS demonstrate samples are clustered first by embryo from
which MEFs were generated. (B) Multidimensional scaling demonstrates
that after correction for embryo from which MEFs were generated samples
cluster according to the transgene which they express.
Additional file 5: Table S2. Differentially expressed genes in primary
wild type MEFs expressing EWS/WT1-KTS or EWS/WT1 + KTS compared to
eGFP controls.
Additional file 6: Table S3. Pathways found to be enriched in MEFs
expressing EWS/WT1-KTS or EWS/WT1 + KTS compared to eGFP controls
on GSEA analysis.
Additional file 7: Table S4. Wnt-pathway genes with differential
expression in five DSRCT samples compared to human fibroblast control.
Additional file 8: Figure S4. DSRCT demonstrate evidence of nuclear
β-catenin immunoreactivity consistent with canonical Wnt pathway
signaling. (A) Sample of DSRCT stained with antibody for β-catenin.
Arrows indicate examples of cells with β-catenin nuclear reactivity,
consistent with canonical Wnt-pathway activation. (B) Control sample of
same tumor stained with secondary antibody only. (C-E) Representative
of a DSRCT that morphologically had two populations of cells, with
evidence of Wnt-activation in one. The upper image (C) depicts the
small round cells characteristic of DSRCT with evidence of β-catenin
nuclear reactivity, consistent with canonical Wnt-pathway activation
while the lower image (E) depicts spindle shaped cells that did not have
evidence of activation of Wnt-pathway signaling with cytoplasmic
staining of β-catenin. (D) Control sample of same tumor stained with
secondary antibody only.
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